Scholar Rock (NASDAQ:SRRK) Announces Earnings Results, Beats Estimates By $0.04 EPS

Scholar Rock (NASDAQ:SRRK) posted its earnings results on Tuesday. The company reported ($0.81) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.04, FiscalAI reports. The company had revenue of $0.57 million for the quarter, compared to analysts’ expectations of $0.30 million. During the same quarter in the prior year, the company earned ($0.90) EPS.

Here are the key takeaways from Scholar Rock’s conference call:

• ISEMBYLD’s U.S. launch showed broad early demand: enrollments came from across the country, included treatment-naive patients as well as children and adults, and reached more than one-third of the top 140 SMA treatment centers within six weeks.
• Access delays are likely to push many initial infusions into 2027. The company said prescription-to-infusion timelines can exceed 60–90 days as patients navigate prior authorization, payer policies, and hospital formularies; an ISEMBYLD-specific J-code is expected April 1, 2027.
• Global regulatory progress advanced: apitegromab’s European application was resubmitted and validated, with a CHMP opinion expected in the first half of 2027, while Japan accepted its application for priority review, supporting a potential launch near year-end 2027.
• The company strengthened its financial position with a $205 million agreement to sell its priority review voucher. Scholar Rock reported $413.6 million in cash, equivalents, and marketable securities at quarter-end and said it does not need an equity offering at this time.
• Pipeline programs continued to progress: dosing began in the phase II FORGE study of apitegromab in FSHD, enrollment is ongoing in the under-two OPAL study, and SRK-439 phase I dosing is progressing, with top-line data expected by year-end and an update planned for early 2027.

Scholar Rock Stock Down 7.9%

NASDAQ:SRRK traded down $4.08 during midday trading on Tuesday, reaching $47.47. 447,577 shares of the stock traded hands, compared to its average volume of 1,456,685. Scholar Rock has a 12-month low of $28.97 and a 12-month high of $61.76. The business has a 50-day moving average of $47.01 and a two-hundred day moving average of $48.22. The company has a debt-to-equity ratio of 0.77, a quick ratio of 7.02 and a current ratio of 7.02. The stock has a market capitalization of $5.78 billion, a PE ratio of -13.77 and a beta of 0.78.

Wall Street Analysts Forecast Growth

SRRK has been the topic of a number of analyst reports. JPMorgan Chase & Co. lifted their price target on Scholar Rock from $63.00 to $70.00 and gave the company an “overweight” rating in a report on Monday, September 21st. Raymond James Financial reissued a “strong-buy” rating on shares of Scholar Rock in a research report on Thursday, October 8th. Truist Financial upped their price objective on Scholar Rock from $76.00 to $77.00 and gave the stock a “buy” rating in a research note on Thursday, September 24th. UBS Group reaffirmed a “buy” rating on shares of Scholar Rock in a research report on Tuesday, September 15th. Finally, Barclays lowered Scholar Rock from an “overweight” rating to a “cautious” rating in a research note on Tuesday, September 15th. Four analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $67.67.

Insiders Place Their Bets

In other news, Director Srinivas Akkaraju purchased 146,970 shares of the business’s stock in a transaction on Monday, October 26th. The shares were acquired at an average cost of $41.59 per share, with a total value of $6,112,482.30. Following the completion of the acquisition, the director owned 6,380,517 shares of the company’s stock, valued at $265,365,702.03. This trade represents a 2.36% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 10.30% of the stock is currently owned by company insiders.

Scholar Rock Company Profile

Scholar Rock is a biopharmaceutical company based in Cambridge, Massachusetts, that develops medicines targeting growth factors and signaling proteins involved in disease. Its research has focused on the transforming growth factor beta (TGF-?) superfamily, which plays roles in processes including muscle development and immune regulation.

The company’s lead program has been apitegromab, a selective inhibitor of myostatin developed for spinal muscular atrophy (SMA). Scholar Rock has studied the medicine as a potential treatment alongside existing SMA therapies, with the goal of improving patients’ motor function.

Scholar Rock was founded in 2012.